Pharmafile Logo

Considerations for Planning Effective and Appealing Advisory Boards: Importance of Participant Preferences

Explore our peer-reviewed article, “Considerations for Planning Effective and Appealing Advisory Boards and Other Small-Group Meetings with Health Care Providers: Importance of Participant Preferences.” Dive into key findings on HCPs’ preferences for virtual and hybrid meetings, revealing their desire for frequent interactions and the impactful use of their insights. Discover why virtual options are favored for their convenience, inclusivity, and lower environmental impact.

Pharmaceutical advisory boards and other small-group meetings with health care providers (HCPs) are important for getting feedback on new clinical trial results, competitors’ products, or educational campaigns. However, they are typically expensive and require participants to travel long distances and take time away from their work and families. For in-person meetings, there are also issues with not everyone being able to contribute as much as they want, and the exclusion of people living in remote or underserved communities is common.

These days, pharmaceutical companies have a choice between hosting meetings in person, virtually, or using a hybrid approach. In making this choice, the cost and organizer’s preference are usually key considerations, but very few people ask the participants what they prefer.

To help answer this question and elucidate the preferred meeting format, frequency, and follow-up approach, we conducted a short feedback survey among HCPs participating in virtual advisory boards in 2022 and 2023. The results were recently published in Pharmaceutical Medicine.

Key findings included that:

  • The majority of health care providers prefer virtual or hybrid pharmaceutical meetings/advisory boards over in-person-only meetings.
  • Health care providers prefer to meet at least 2–4 times per year and want to receive continuous updates on how the pharmaceutical company is using their insights.
  • Key benefits of virtual versus in-person meetings include their superior convenience and flexibility, low environmental impact, and the ability to hear from more diverse participants.

Access the full article here, titled Considerations for Planning Effective and Appealing Advisory Boards and Other Small-Group Meetings with Health Care Providers: Importance of Participant Preferences.

This content was provided by Impetus Digital

Company Details

 Latest Content from  Impetus Digital 

Gene Editing and Precision Medicine: The Future of Healthcare?

Dr. Oscar Segurado, Chief Medical Officer at ASC Therapeutics, dives into advanced gene therapies, gene editing, and personalized medicine. We also explore the many different hats he wears as CMO, consultant,...

CRM Design and Optimization for Life Science Organizations

John Leombruno, CEO of OkRx, shares how his company is working to improve PSP strategy and operations in Canada. He also discusses the impact of COVID-19 on PSPs, digital transformation, clinical...

Enabling Patient-Focused Research Through Virtual Clinical Trials

Chad Walsh, CEO of Sciteline, dives into virtual trials, including their benefits, barriers, and impact on patient-centricity. Among other things, we will discuss data privacy concerns, the role of digital...

Innovative Approaches to Managing Mental Health Conditions

Owen Muir, MD, CIO at Brooklyn Minds, explores the secondary effects of COVID-19 on mental health conditions, along with techniques such as deep Transcranial Magnetic Stimulation (dTMS), Mentalization-Based Treatment (MBT), and...

Looking back at the year when everything changed

COVID-19 has impacted every aspect of our lives, from the way we shop for groceries to the way we conduct work and interact with healthcare providers and our families.

PRESS RELEASE: IMPETUS DIGITAL LAUNCHES INSITE EVENTâ„¢

Impetus Digital launches InSite Event™ -  the most comprehensive virtual event platform for life science companies, delivered with white glove service

Risk Management, Ethics, and Compliance Considerations in the New Normal

Myriam Prescott, Head of Ethics, Risks and Compliance - Oncology, Novartis Canada, dissects the importance of effective patient engagement and strong compliance & monitoring programs. We also dive into the...

A Deep-Dive into the COVID-19 Pandemic and its Secondary Effects

Dr. Farah Fourcand, Author of Pandemic Manifesto, shares her experience working on the frontlines of the COVID-19 pandemic. She also dives into the psychological impact of COVID-19, lessons learned from the...

Women in Leadership: Barriers & Opportunities in the Life Science Industry

Allison Gaw, Executive Director, Corporate and Business Development at Chinook Therapeutics, discusses women in STEM, effective leadership, cross-border collaboration during COVID-19, the future of healthcare, and much more.

Highlighting Patient Voices, Workforce Well-Being & Health Literacy During & After the Pandemic

We explore the importance of health literacy, patient voices, and workforce wellbeing during COVID-19 with Deborah Collyar (Patient Advocates in Research), Cathryn Gunther (Population Health Alliance) & Catina O'Leary (Health...